Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to determine the short and long term side effects of a very intensive treatment, which includes combinations of chemotherapy drugs followed by radiation therapy and two transplants supported by peripheral blood progenitor cells (stem cells), for children with advanced stage neuroblastoma and sarcomas.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborators: Boston Children's Hospital; Boston Children’s Hospital; Children's Hospital of Philadelphia
• Treatments: Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Ifosfamide; Lenograstim; Melphalan; Sargramostim; Vincristine

Criteria

Inclusion Criteria:

• Previously untreated neuroblastoma Stage D > 365 days

• Previously untreated neuroblastoma Stage C at age > 365 days with n-myc amplification

• Previously untreated metastatic Ewings sarcoma/PNET

• Previously untreated non-rhabdomyosarcoma soft tissue sarcoma

• Confirmation of neuroblastoma at time of diagnosis by histologic specimen or with bone marrow specimen showing solid tumor. Confirmation of sarcoma by histologic specimen with evidence of metastatic disease be imaging study

• Patient 19 years of age or younger

• ANC > 1000

• Platelet count > 75,000

• SGOT < 2.5 x ULN

• Normal serum creatinine levels for age

Exclusion Criteria:

• Previous malignancy requiring nonsurgical treatment or bone marrow transplant.

• Relapsed disease